Learning and Development
At Sungen Biomedical, people are the most valuable resource driving innovation in therapeutic antibody development. For this reason we have built a comprehensive and forward-looking learning and development system that aims to train experts in antibody science and innovative managers at industry-leading levels. The following are the core elements of our learning and development plan:
First Show Vienna! Phase I Clinical Data of the World's First Antibody Drug SGC001 for Acute Myocardial Infarction Unveiled BIO Europe2025
On November 3, 2025, Vienna time, Sungen announced the Phase I clinical results of SGC001 Injection, the world's first antibody drug for acute myocardial infarction, at the 31st BIO Europe 2025, h...
Home
FIC! Sungen Biomedical's SGC001 Injection is Approved for Clinical Trials, Achieving Two Approvals Both in China and the United States!
On August 05, 2024, the world's first innovative drug SGC001 injection obtained the clinical trial implied approval from the Center for Drug Evaluation (CDE). The drug is developed by Beijing Sung...
